Targeting One of the Most Aggressive Brain Cancers
GBM
Understanding Glioblastoma
Glioblastoma (GBM) is the most aggressive and common form of malignant brain cancer in adults. It is characterized by rapid growth, complex biology, and a high rate of recurrence.
Despite advances in surgery, radiation, and chemotherapy, outcomes remain poor, and effective long-term treatment options are limited.
The Challenge
Why Glioblastoma Is So Difficult to Treat
- Tumors rapidly adapt and develop resistance
- Multiple signaling pathways drive tumor survival
- The blood-brain barrier restricts drug delivery
- High recurrence rates after treatment
A Different Strategy for a Complex Disease
Tactical Therapeutics is developing CTO, a novel therapy designed to target calcium (ca)²⁺ signaling—a central mechanism involved in tumor growth and resistance.
Rather than focusing on a single pathway, CTO works across multiple biological processes, aiming to disrupt the tumor’s ability to survive and adapt.
Why CTO Matters for GBM
Designed for Brain Tumors
CTO offers several key advantages that make it especially promising for glioblastoma treatment:
- Crosses the blood-brain barrier effectively
- Targets multiple cancer pathways simultaneously
- Oral therapy with a favorable safety profile
- Designed to overcome treatment resistance
Clinical Progress
Encouraging Results in Advanced Patients
Clinical studies of CTO have shown promising outcomes in patients with advanced solid tumors, newly diagnosed and recurrent glioblastoma.
Advancing Toward the Future of GBM Treatment
Tactical Therapeutics is continuing to advance its clinical program with the goal of bringing CTO to patients in need.
By targeting the underlying mechanisms of resistance, we aim to redefine what is possible in the treatment of glioblastoma.
Glioblastoma has long been one of the most challenging cancers to treat. Tactical Therapeutics is working to change that—through innovation, precision science, and a commitment to better outcomes.